Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits

Olkkonen, 2018, New medications targeting triglyceride-rich lipoproteins: can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?, Atherosclerosis, 272, 27, 10.1016/j.atherosclerosis.2018.03.019 Ladeiras-Lopes, 2015, Atherosclerosis: recent trials, new targets and future directions, Int J Cardiol, 192, 72, 10.1016/j.ijcard.2015.05.013 Toth, 2013, High-density lipoproteins: a consensus statement from the National Lipid Association, J Clin Lipidol, 7, 484, 10.1016/j.jacl.2013.08.001 Karathanasis, 2017, The changing face of HDL and the best way to measure it, Clin Chem, 63, 196, 10.1373/clinchem.2016.257725 Talbot, 2018, Determinants of cholesterol efflux capacity in humans, Prog Lipid Res, 69, 21, 10.1016/j.plipres.2017.12.001 Khera, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis, N Engl J Med, 364, 127, 10.1056/NEJMoa1001689 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579 Rader, 2012, The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis?, Nat Med, 18, 1344, 10.1038/nm.2937 Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 Mora, 2013, High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy, Circulation, 128, 1189, 10.1161/CIRCULATIONAHA.113.002671 Calabresi, 2011, Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk, J Lipid Res, 52, 1569, 10.1194/jlr.P014977 Haase, 2012, LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals, J Clin Endocrinol Metab, 97, E248, 10.1210/jc.2011-1846 Calabresi, 2015, HDL and atherosclerosis: insights from inherited HDL disorders, Biochim Biophys Acta, 1851, 13, 10.1016/j.bbalip.2014.07.015 Murphy, 2012, Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells, Biochim Biophys Acta, 1821, 513, 10.1016/j.bbalip.2011.08.003 Luscher, 2014, High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target, Circ Res, 114, 171, 10.1161/CIRCRESAHA.114.300935 Pirillo, 2015, HDL in infectious diseases and sepsis, Handb Exp Pharmacol, 224, 483, 10.1007/978-3-319-09665-0_15 Parolini, 2008, J Am Coll Cardiol, 51, 1098, 10.1016/j.jacc.2007.12.010 Parolini, 2009, HDL therapy for the treatment of cardiovascular diseases, Curr Vasc Pharmacol, 7, 550, 10.2174/157016109789043856 Takata, 2018, High-density lipoprotein infusions, Cardiol Clin, 36, 311, 10.1016/j.ccl.2017.12.012 Graversen, 2008, Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties, J Cardiovasc Pharmacol, 51, 170, 10.1097/FJC.0b013e31815ed0b9 Chiesa, 2008, Acute effects of high-density lipoproteins: biochemical basis and clinical findings, Curr Opin Cardiol, 23, 379, 10.1097/HCO.0b013e3283007ccd Marchesi, 2011, The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease, Biochim Biophys Acta, 1812, 87, 10.1016/j.bbadis.2010.07.002 Ohnsorg, 2011, Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin: cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells, Biochim Biophys Acta, 1811, 1115, 10.1016/j.bbalip.2011.09.001 Murphy, 2013, Anti-inflammatory functions of apolipoprotein A-I and high-density lipoprotein are preserved in trimeric apolipoprotein A-I, J Pharmacol Exp Ther, 344, 41, 10.1124/jpet.112.199257 Jonas, 1986, Reconstitution of high-density lipoproteins, Methods Enzymol, 128, 553, 10.1016/0076-6879(86)28092-1 Chiesa, 2001, Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound, Atherosclerosis, 156, 277, 10.1016/S0021-9150(00)00655-9 Chiesa, 2004, Evaluation of a soft atherosclerotic lesion in the rabbit aorta by an invasive IVUS method versus a non-invasive MRI technology, Atherosclerosis, 174, 25, 10.1016/j.atherosclerosis.2004.01.018 Marchesi, 2011, Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL, Br J Pharmacol, 164, 1460, 10.1111/j.1476-5381.2011.01429.x Parolini, 2012, Cholesterol-lowering effect of dietary lupinus angustifolius proteins in adult rats through regulation of genes involved in cholesterol homeostasis, Food Chem, 132, 1475, 10.1016/j.foodchem.2011.12.004 Parolini, 2013, Effect of the combinations between pea proteins and soluble fibres on cholesterolaemia and cholesterol metabolism in rats, Br J Nutr, 110, 1394, 10.1017/S0007114513000639 Parolini, 2014, A salmon protein hydrolysate exerts lipid-independent anti-atherosclerotic activity in ApoE-deficient mice, PLoS One, 9, 10.1371/journal.pone.0097598 Parolini, 2014, Magnetic resonance imaging visualization of vulnerable atherosclerotic plaques at the brachiocephalic artery of apolipoprotein E knockout mice by the blood-pool contrast agent B22956/1, Mol Imaging, 13, 1, 10.2310/7290.2014.00012 Busnelli, 2017, Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE(-/-) mice, Sci Rep, 7, 44503, 10.1038/srep44503 Caligari, 2006, Lupin (Lupinus albus) protein isolate has adequate nutritional value and reduces large intestinal weight in rats after restricted and ad libitum feeding, Ann Nutr Metab, 50, 528, 10.1159/000098145 de la Llera-Moya, 2010, The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages, Arterioscler Thromb Vasc Biol, 30, 796, 10.1161/ATVBAHA.109.199158 Favari, 2013, ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects, J Lipid Res, 54, 238, 10.1194/jlr.P030452 Chiesa, 2002, Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks, Circ Res, 90, 974, 10.1161/01.RES.0000018422.31717.EE Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Jensen, 2004, Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study, Circulation, 110, 265, 10.1161/01.CIR.0000135215.75876.41 Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA, 297, 1675, 10.1001/jama.297.15.jpc70004 Stegman, 2016, Coronary atheroma progression rates in men and women following high-intensity statin therapy: a pooled analysis of REVERSAL, ASTEROID and SATURN, Atherosclerosis, 254, 78, 10.1016/j.atherosclerosis.2016.09.059 Braschi, 2000, Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney, Biochemistry, 39, 5441, 10.1021/bi9919504 Miyazaki, 1995, Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits, Arter Thromb Vasc Biol, 15, 1882, 10.1161/01.ATV.15.11.1882 Regenass-Lechner, 2016, Immunogenicity, inflammation, and lipid accumulation in cynomolgus monkeys infused with a lipidated tetranectin-apoA-I fusion protein, Toxicol Sci, 150, 378, 10.1093/toxsci/kfw004 Kataoka, 2017, Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden, Cardiovasc Diagn Ther, 7, 252, 10.21037/cdt.2017.02.01 Karalis, 2018, HDL mimetics infusion and regression of atherosclerosis: is it still considered a valid therapeutic option?, Curr Cardiol Rep, 20, 66, 10.1007/s11886-018-1004-9 Westerterp, 2014, ATP-binding cassette transporters, atherosclerosis, and inflammation, Circ Res, 114, 157, 10.1161/CIRCRESAHA.114.300738 Brownell, 2016, Modulating cholesterol efflux capacity to improve cardiovascular disease, Curr Opin Lipidol, 27, 398, 10.1097/MOL.0000000000000317 Kempen, 2016, Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients, Atherosclerosis, 255, 17, 10.1016/j.atherosclerosis.2016.10.042 Gille, 2018, CSL112 (apolipoprotein A-I [human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients, Arter Thromb Vasc Biol, 38, 953, 10.1161/ATVBAHA.118.310538 Favari, 2009, Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1, Biochemistry, 48, 11067, 10.1021/bi901564g Rothblat, 1999, Cell cholesterol efflux: integration of old and new observations provides new insights, J Lipid Res, 40, 781, 10.1016/S0022-2275(20)32113-1 Phillips, 2014, Molecular mechanisms of cellular cholesterol efflux, J Biol Chem, 289, 24020, 10.1074/jbc.R114.583658 Ronsein, 2016, Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects, Arter Thromb Vasc Biol, 36, 404, 10.1161/ATVBAHA.115.306268 Group, 2014, Effects of extended-release niacin with laropiprant in high-risk patients, N Engl J Med, 371, 203, 10.1056/NEJMoa1300955 Patel, 2010, Anti-inflammatory effects of apolipoprotein A-I in the rabbit, Atherosclerosis, 212, 392, 10.1016/j.atherosclerosis.2010.05.035 Giannarelli, 2012, Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term, Thromb Haemost, 108, 1246, 10.1160/TH12-08-0556 Adorni, 2011, Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism, Atherosclerosis, 215, 70, 10.1016/j.atherosclerosis.2010.12.004 Moore, 2013, Macrophages in atherosclerosis: a dynamic balance, Nat Rev Immunol, 13, 709, 10.1038/nri3520